Literature DB >> 26951159

A case series of re-establishment of neuromuscular block with rocuronium after sugammadex reversal.

Hajime Iwasaki1, Tomoki Sasakawa2, Kenichi Takahoko2, Shunichi Takagi3, Hideki Nakatsuka4, Takahiro Suzuki5, Hiroshi Iwasaki2.   

Abstract

We report the use of rocuronium to re-establish neuromuscular block after reversal with sugammadex. The aim of this study was to investigate the relationship between the dose of rocuronium needed to re-establish neuromuscular block and the time interval between sugammadex administration and re-administration of rocuronium. Patients who required re-establishment of neuromuscular block within 12 h after the reversal of rocuronium-induced neuromuscular block with sugammadex were included. After inducing general anesthesia and placing the neuromuscular monitor, the protocol to re-establish neuromuscular block was as follows. An initial rocuronium dose of 0.6 mg/kg was followed by additional 0.3 mg/kg doses every 2 min until train-of-four responses were abolished. A total of 11 patients were enrolled in this study. Intervals between sugammadex and second rocuronium were 12-465 min. Total dose of rocuronium needed to re-establish neuromuscular block was 0.6-1.2 mg/kg. 0.6 mg/kg rocuronium re-established neuromuscular block in all patients who received initial sugammadex more than 3 h previously. However, when the interval between sugammadex and second rocuronium was less than 2 h, more than 0.6 mg/kg rocuronium was necessary to re-establish neuromuscular block.

Entities:  

Keywords:  Repeat surgery; Rocuronium; Sugammadex

Mesh:

Substances:

Year:  2016        PMID: 26951159     DOI: 10.1007/s00540-016-2159-4

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  17 in total

1.  A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host.

Authors:  Anton Bom; Mark Bradley; Ken Cameron; John K Clark; Jan Van Egmond; Helen Feilden; Elizabeth J MacLean; Alan W Muir; Ronald Palin; David C Rees; Ming-Qiang Zhang
Journal:  Angew Chem Int Ed Engl       Date:  2002-01-18       Impact factor: 15.336

2.  Neuromuscular block: views from the Western pacific.

Authors:  Malcolm Futter; Tony Gin
Journal:  Anesth Analg       Date:  2010-07       Impact factor: 5.108

3.  Recovery from neuromuscular blockade: a survey of practice.

Authors:  M Grayling; B P Sweeney
Journal:  Anaesthesia       Date:  2007-08       Impact factor: 6.955

4.  Non-steroidal neuromuscular blocking agents to re-establish paralysis after reversal of rocuronium-induced neuromuscular block with sugammadex.

Authors:  Hans D de Boer; Jacques J Driessen; Jan van Egmond; Leo H D J Booij
Journal:  Can J Anaesth       Date:  2008-02       Impact factor: 5.063

5.  Knowledge of residual curarization: an Italian survey.

Authors:  P Di Marco; G Della Rocca; F Iannuccelli; L Pompei; C Reale; P Pietropaoli
Journal:  Acta Anaesthesiol Scand       Date:  2009-10-15       Impact factor: 2.105

6.  First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide.

Authors:  Francois Gijsenbergh; Steven Ramael; Natalie Houwing; Thijs van Iersel
Journal:  Anesthesiology       Date:  2005-10       Impact factor: 7.892

7.  Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block.

Authors:  Stefan J Schaller; Heidrun Fink; Kurt Ulm; Manfred Blobner
Journal:  Anesthesiology       Date:  2010-11       Impact factor: 7.892

8.  Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation.

Authors:  Adrienn Pongrácz; Szilárd Szatmári; Réka Nemes; Béla Fülesdi; Edömér Tassonyi
Journal:  Anesthesiology       Date:  2013-07       Impact factor: 7.892

9.  Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block.

Authors:  Yoshifumi Kotake; Ryoichi Ochiai; Takahiro Suzuki; Setsuro Ogawa; Shunichi Takagi; Makoto Ozaki; Itsuo Nakatsuka; Junzo Takeda
Journal:  Anesth Analg       Date:  2013-06-11       Impact factor: 5.108

10.  Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients.

Authors:  Benoît Plaud; Olli Meretoja; Rainer Hofmockel; Julien Raft; Peter A Stoddart; Jacqueline H M van Kuijk; Yvonne Hermens; Rajinder K Mirakhur
Journal:  Anesthesiology       Date:  2009-02       Impact factor: 7.892

View more
  5 in total

1.  The use of succinylcholine after sugammadex reversal.

Authors:  Chie Asakura; Hajime Iwasaki
Journal:  J Anesth       Date:  2016-06-13       Impact factor: 2.078

Review 2.  Sugammadex: A Review of Neuromuscular Blockade Reversal.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

Review 3.  A practical guide for anesthetic management during intraoperative motor evoked potential monitoring.

Authors:  Masahiko Kawaguchi; Hiroki Iida; Satoshi Tanaka; Naokazu Fukuoka; Hironobu Hayashi; Shunsuke Izumi; Kenji Yoshitani; Manabu Kakinohana
Journal:  J Anesth       Date:  2019-10-19       Impact factor: 2.078

4.  Use of intraoperative neuromuscular monitor reduces the reversal dose of sugammadex: a single-center retrospective study.

Authors:  Hajime Iwasaki; Atsushi Kurosawa; Takafumi Iida; Tomoki Sasakawa; Hirotsugu Kanda
Journal:  J Anesth       Date:  2020-01-28       Impact factor: 2.078

Review 5.  Preparing for the unexpected: special considerations and complications after sugammadex administration.

Authors:  Hajime Iwasaki; J Ross Renew; Takayuki Kunisawa; Sorin J Brull
Journal:  BMC Anesthesiol       Date:  2017-10-17       Impact factor: 2.217

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.